Evidence map›Paper›PMID 42101051›Full record

Observational studyInfluenza and other respiratory viruses2026

Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV-HAT).

Kanrutai Jarottammarat, Kanokkarn Pinyopornpanish, Chadakan Yan, Bussakorn Mahakkanukrauh, Otavio Cintra, Adriana Guzman-Holst, Phichayut Phinyo, Wipa Reechaipichitkul

Abstract readObservational Study
In one paragraph

Observational study in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kanrutai JarottammaratDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.ORCID https://orcid.org/0009-0008-6444-6542
Kanokkarn PinyopornpanishAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0009-0009-8098-9288
Chadakan YanMedical Affairs, Vaccines, GSK, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-5347-5822
Bussakorn MahakkanukrauhMedical Affairs, Vaccines, GSK, Bangkok, Thailand.ORCID https://orcid.org/0009-0000-4311-1710
Otavio CintraMedical Affairs, Vaccines, International, GSK, Sao Paulo, Brazil.ORCID https://orcid.org/0000-0002-3485-8780
Adriana Guzman-HolstRWE & HO Research, GSK, London, UK.ORCID https://orcid.org/0000-0002-6753-2541
Phichayut PhinyoCenter for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0002-8543-6254
Wipa ReechaipichitkulDivision of Pulmonary Medicine and Pulmonary Critical Care, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.ORCID https://orcid.org/0000-0002-4536-6773

Funding

GlaxoSmithKline (GSK Study ID VEO-002142)
6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI) in adults, especially older individuals, yet data on burden in Thailand are limited. This study aimed to describe clinical characteristics and mortality risk factors of RSV-related hospitalizations in Thai adults.

methodsWe conducted a retrospective analysis using Thailand's national hospital database, including adults aged ≥ 18 years hospitalized with RSV-associated ARIs between June 2016 and September 2024, identified using ICD-10 codes J12.1, J20.5, J21.0, and B97.4. Demographics, case fatality ratio, and healthcare resource utilization were assessed. Multivariable logistic regression identified predictors of in-hospital mortality, and Kaplan-Meier analysis estimated 60-day overall survival by age and comorbidity status.

resultsAmong 1595 RSV-related hospitalizations, the mean age was 66.5 years; 72.0% were aged ≥60 years and 78.4% had ≥ 1 comorbidity, most commonly hypertension, diabetes, chronic respiratory disease, and chronic heart disease. The median length of stay (LOS) was 7 days, 17.3% required oxygen therapy, and 8.2% received invasive mechanical ventilation (IMV). The in-hospital mortality was 9.53%. Mortality was independently associated with age ≥ 75 years (mOR 1.83, p = 0.019), LOS ≥ 7 days (1.95, p = 0.001), IMV (2.94, p < 0.001), pneumonia (4.10, p < 0.001), and acute myocardial infarction (3.05, p = 0.005). The 60-day survival rate was 88.2%, declining to 84.0% in patients aged ≥ 75 years (p < 0.001) and 87.1% in those with comorbidities versus 92.2% in those without (p = 0.013).

conclusionsRSV causes substantial morbidity and mortality in Thai adults, especially those aged ≥ 75 years and with chronic comorbidities, underscoring the need for strengthened RSV surveillance and prevention strategies.

trial registrationThai Clinical Trials Registry: TCTR20250929005.

Indexed as

HospitalizationRespiratory Syncytial Virus InfectionsAdolescentAdultAgedAged, 80 and overFemaleHospital MortalityHumansLength of StayMaleMiddle AgedRespiratory Syncytial Virus, HumanRetrospective StudiesRisk FactorsThailandadulthospitalizationmortalityrespiratory syncytial virusThailand

Identifiers

PMID42101051
PMCPMC13154378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.